Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1963 1
1964 1
1973 2
1975 1
1976 1
1977 4
1979 1
1983 5
1984 6
1985 5
1986 5
1987 7
1988 12
1989 12
1990 14
1991 15
1992 12
1993 9
1994 19
1995 20
1996 19
1997 7
1998 21
1999 16
2000 20
2001 29
2002 32
2003 42
2004 22
2005 40
2006 33
2007 35
2008 48
2009 36
2010 36
2011 38
2012 42
2013 32
2014 48
2015 61
2016 72
2017 82
2018 75
2019 88
2020 117
2021 100
2022 123
2023 132
2024 121

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,556 results

Results by year

Filters applied: . Clear all
Page 1
MK-7 and Its Effects on Bone Quality and Strength.
Sato T, Inaba N, Yamashita T. Sato T, et al. Among authors: yamashita t. Nutrients. 2020 Mar 31;12(4):965. doi: 10.3390/nu12040965. Nutrients. 2020. PMID: 32244313 Free PMC article. Review.
Vitamin K acts as a cofactor and is required for post-translational gamma-carboxylation of vitamin K-dependent proteins (VKDP). ...Among the several vitamin K homologs, only MK-7 (vitamin K2) can promote gamma-carboxylation of extrahepatic VKDPs, OC, and the …
Vitamin K acts as a cofactor and is required for post-translational gamma-carboxylation of vitamin K-dependent proteins (VKDP) …
Structural basis for ion selectivity in potassium-selective channelrhodopsins.
Tajima S, Kim YS, Fukuda M, Jo Y, Wang PY, Paggi JM, Inoue M, Byrne EFX, Kishi KE, Nakamura S, Ramakrishnan C, Takaramoto S, Nagata T, Konno M, Sugiura M, Katayama K, Matsui TE, Yamashita K, Kim S, Ikeda H, Kim J, Kandori H, Dror RO, Inoue K, Deisseroth K, Kato HE. Tajima S, et al. Among authors: yamashita k. Cell. 2023 Sep 28;186(20):4325-4344.e26. doi: 10.1016/j.cell.2023.08.009. Epub 2023 Aug 30. Cell. 2023. PMID: 37652010 Free PMC article.
KCR channelrhodopsins (K(+)-selective light-gated ion channels) have received attention as potential inhibitory optogenetic tools but more broadly pose a fundamental mystery regarding how their K(+) selectivity is achieved. ...Thus, discovery of a mechanism for ion- …
KCR channelrhodopsins (K(+)-selective light-gated ion channels) have received attention as potential inhibitory optogenetic tools but …
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S, Masuda D, Matsuzawa Y. Yamashita S, et al. Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5. Curr Atheroscler Rep. 2020. PMID: 31974794 Free PMC article. Review.
To resolve these issues, the concept of selective PPARalpha modulator (SPPARMalpha) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. RECENT FINDINGS: Pemafibrate, one of SPPARMsalpha, was synthesized by Kowa Compa …
To resolve these issues, the concept of selective PPARalpha modulator (SPPARMalpha) with a superior balance of efficacy and safety has been …
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.
Li M, Nishimura T, Takeuchi Y, Hongu T, Wang Y, Shiokawa D, Wang K, Hirose H, Sasahara A, Yano M, Ishikawa S, Inokuchi M, Ota T, Tanabe M, Tada KI, Akiyama T, Cheng X, Liu CC, Yamashita T, Sugano S, Uchida Y, Chiba T, Asahara H, Nakagawa M, Sato S, Miyagi Y, Shimamura T, Nagai LAE, Kanai A, Katoh M, Nomura S, Nakato R, Suzuki Y, Tojo A, Voon DC, Ogawa S, Okamoto K, Foukakis T, Gotoh N. Li M, et al. Among authors: yamashita t. J Clin Invest. 2023 Nov 15;133(22):e166666. doi: 10.1172/JCI166666. J Clin Invest. 2023. PMID: 37966117 Free PMC article.
Importantly, FXYD3+ CSCs were sensitive to senolytic Na+/K+ pump inhibitors, such as cardiac glycosides. Together, our data indicate that FXYD3+ CSCs with ancestral features are drivers of plasticity and chemoresistance in TNBC. Targeting the Na+/K+ pump could be an …
Importantly, FXYD3+ CSCs were sensitive to senolytic Na+/K+ pump inhibitors, such as cardiac glycosides. Together, our data indicate …
Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2.
Sueta D, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Kaneda K, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Shioyama W, Dohke T, Nishikawa R, Kimura T, Tsujita K; COMMAND VTE Registry-2 Investigators. Sueta D, et al. Among authors: yamashita y. Thromb Haemost. 2024 Nov;124(11):1013-1023. doi: 10.1055/a-2316-5269. Epub 2024 Apr 29. Thromb Haemost. 2024. PMID: 38684190
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. Hashimoto T, et al. Among authors: yamashita r. Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206. Cancer Discov. 2024. PMID: 39023403 Free PMC article.
Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1.
Wakabayashi T, Takahashi M, Okazaki H, Okazaki S, Yokote K, Tada H, Ogura M, Ishigaki Y, Yamashita S, Harada-Shiba M; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare of Japan. Wakabayashi T, et al. Among authors: yamashita s. J Atheroscler Thromb. 2024 Jul 1;31(7):1005-1023. doi: 10.5551/jat.RV22018. Epub 2024 May 3. J Atheroscler Thromb. 2024. PMID: 38710625 Free PMC article. Review.
Cathepsin K and the design of inhibitors of cathepsin K.
Yamashita DS, Dodds RA. Yamashita DS, et al. Curr Pharm Des. 2000 Jan;6(1):1-24. doi: 10.2174/1381612003401569. Curr Pharm Des. 2000. PMID: 10637370 Review.
Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been characterized. ...Knockout of cathepsin K in the mouse also results in retarded bone …
Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathep …
1,556 results